@article{992df8b003084767a79530a18c2a693b,
title = "Selective macrocyclic peptide modulators of Lys63-linked ubiquitin chains disrupt DNA damage repair",
abstract = "Developing an effective binder for a specific ubiquitin (Ub) chain is a promising approach for modulating various biological processes with potential applications in drug discovery. Here, we combine the Random Non-standard Peptides Integrated Discovery (RaPID) method and chemical protein synthesis to screen an extended library of macrocyclic peptides against synthetic Lys63-linked Di-Ub to discover a specific binder for this Ub chain. Furthermore, next-generation binders are generated by chemical modifications. We show that our potent cyclic peptide is cell-permeable, and inhibits DNA damage repair, leading to apoptotic cell death. Concordantly, a pulldown experiment with the biotinylated analog of our lead cyclic peptide supports our findings. Collectively, we establish a powerful strategy for selective inhibition of protein-protein interactions associated with Lys63-linked Di-Ub using cyclic peptides. This study offers an advancement in modulating central Ub pathways and provides opportunities in drug discovery areas associated with Ub signaling.",
author = "Vamisetti, {Ganga B.} and Abhishek Saha and Huang, {Yichao J.} and Rajeshwer Vanjari and Guy Mann and Julia Gutbrod and Nabieh Ayoub and Hiroaki Suga and Ashraf Brik",
note = "Funding Information: A.B. holds the Jordan and Irene Tark Academic Chair. This project has received funding from Japan Agency for Medical Research and Development (AMED), Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research) under JP21am0101090 to H.S. We also acknowledge BioRender.com for assistance in schematic figure preparation. We also acknowledge the Smoler Proteomics Centre at Technion for proteomics analysis. Funding Information: A.B. holds the Jordan and Irene Tark Academic Chair. This project has received funding from Japan Agency for Medical Research and Development (AMED), Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research) under JP21am0101090 to H.S. We also acknowledge BioRender.com for assistance in schematic figure preparation. We also acknowledge the Smoler Proteomics Centre at Technion for proteomics analysis. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
day = "1",
doi = "10.1038/s41467-022-33808-6",
language = "English",
volume = "13",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",
}